Trials / Completed
CompletedNCT00097968
Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
An Open-Label, Single Arm, Pilot Study of the Renal Safety of Everolimus in Addition to Neoral® in Cardiac Transplant Recipients With Established Allograft Vasculopathy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Everolimus is an immunosuppressive drug that is being studied for preventing acute rejection that can happen after heart transplantation. It is usually used in combination with other immunosuppressive drugs such as cyclosporine. The purpose of this study is to evaluate the change in kidney function after beginning everolimus, while determining the most effective Neoral® (cyclosporine) dose to take with everolimus, in adult cardiac transplant patients who have had their transplanted heart for at least 1 year and who have cardiac allograft vasculopathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | everolimus |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2005-04-01
- First posted
- 2004-12-02
- Last updated
- 2010-07-12
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00097968. Inclusion in this directory is not an endorsement.